Prognostic/predictive factors in breast cancer

Clinics in Laboratory Medicine

Volumn 25, Issue 4, 2005, Pages 809-825

  Masood, Shahla ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HORMONAL THERAPY; HUMAN; LYMPH NODE; NONHUMAN; ONCOGENE NEU; ORCHIECTOMY; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

AXILLA; BREAST NEOPLASMS; CELL PROLIFERATION; DNA; FEMALE; HUMANS; LYMPH NODES; PLOIDIES; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27944500274     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2005.08.012     Document Type: Review

References (112)

1. Early Breast Cancer Trialists' Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women N Engl J Med 319 1988 1681 1692
2. G. Bonadonna, P. Valagussa, and G. Tancini Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast ancer NCI Monogr 1 1986 45 49
3. B. Fisher, J. Costantino, and C. Redmond A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 320 1989 479 484
4. B. Fisher, C. Redmond, and N.Y. Dimitrov A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor negative tumors N Engl J Med 320 1989 473 478
5. E.G. Mansour, R. Gray, and A.H. Shatila Efficiency of adjuvant chemotherapy in high-risk node negative breast cancer. An intergroup study N Engl J Med 320 1989 485 490
6. NIH Consensus Conference Treatment of early stage breast cancer JAMA 265 1991 391 395
7. D.L. Page Prognosis and breast cancer - recognition of lethal and favorable prognostic types Am J Surg Pathol 15 1991 334 349
8. G. Bonadonna Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer J Clin Oncol 7 1989 1380 1397
9. R.E. Wilson, W.L. Donegan, and C. Mettlin The 182 National Survey of Carcinoma of the Breast in the United States by the American College of Surgeons Surg Gynecol Obstet 159 1984 309 318
10. B. Fisher, N. Slack, and D. Katrych Ten year follow-up results of patients with carcinoma in the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy Surg Gynecol Obstet 140 1975 528 534
11. F.F. Atliyeh, M. Jensen, and A.G. Huvos Axillary micrometastases and macrometastasis in carcinoma of the breast Surg Gynecol Obstet 144 1977 839 842
12. S.J. Cutler, C. Zipin, and A.J. Asire The prognostic significance of palpable lymph nodes in cancer of the breast Cancer 23 1969 243 250
13. R. Bettelheim, K.N. Price, and R.D. Gelber International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer Lancet 335 1990 1565 1568
14. A.M. Neville, K.N. Price, and R.D. Gleber Axillary node micrometastasis and breast cancer Lancet 337 1991 1110
15. M. Trojani, I. de Mascarel, and F. Bonichon Micrometastasis to axillary lymph nodes from carcinoma of breast. Detection by immunohistochemistry and prognostic significance Br J Cancer 55 1987 303 306
16. C.A. Wells, A. Herget, and J. Brochier The immunocytochemical detection of axillary micrometastasis in breast cancer Br J Cancer 50 1984 193 197
17. W.L. Donegan Staging and primary treatment W.L. Donegan J.S. Spratt Cancer of the breast 1988 WB Saunders Philadelphia 336 402
18. C.L. Carter, C. Allen, and D.E. Henson Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 1989 181 187
19. W.L. McGuire Prognostic factors in primary breast cancer Cancer Surv 5 1986 527 536
20. B. Fisher, N.H. Slack, and I.D.J. Brass Cancer of the breast: size of neoplasm and prognosis Cancer 24 1969 1071 1080
21. S. Koscielny, M. Tubiana, and M.G. Le Breast cancer: relationship between the size of the primary tumor and the probability of metstatic dissemination Br J Cancer 49 1984 709 715
22. P.P. Rosen, S. Groshen, and P.E. Saigo A long term follow-up study of survival in Stage I (T1N0M0) and Stage II (T1N0M0) breast carcinoma J Clin Oncol 7 1989 355 366
23. P.P. Rosen, S. Groshen, and P.E. Saigo Pathological prognostic factors in Stage I (T1N0M0) and Stage II (T1N0M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years J Clin Oncol 7 1989 1239 1251
24. L. Bondensen, and K. Lindholm Aspiration cytology of tubular breast carcinoma Acta Cytol 34 1989 15 20
25. R.R. Baker Unusual lesions and their management Surg Clin North Am 70 1990 963 975
26. C.M. Hunt, I.O. Ellis, and C.W. Elston Cytological grading of breast carcinoma: a feasible proposition? Cytopathology 1 1990 287 295
27. Howart AJ, Armstrong GR, Briggs WA, et al. Fine needle aspiration of palpable breast lumps: a 1-year audit using the cytospin method. Cytopathology 1992;3:17-22.
28. D.J. Dabbs Duct carcinoma of breast: nuclear grade as predictor of S-phase fraction Hum Pathol 24 1993 652 656
29. J.A. Robinson, G. McKee, and A. Nichols Prognostic value of cytological grading of fine needle aspirates from breast carcinomas Lancet 343 1994 947 949
30. E.R. Fisher, C. Redmond, and B. Fisher Histologic grading of breast cancer Pathol Annu 15 1980 239 251
31. S. Masood Prognostic value of nuclear grading in breast cytology Mod Pathol 10 3 1994 263 267
32. L.P. Howell, R. Gandour-Edwards, and D. O'Sullivan Applicatoin of the Scarff-Bloom-Richardson tumor grading system to fine needle aspirates of the breast Am J Clin Pathol 101 1994 262 265
33. D.J. Dabbs, and J.F. Silverman Prognostic factors from the fine needle aspirate: breast carcinoma nuclear grade Diagn Cytopathol 10 1994 203 208
34. R.S. Cajulis, N. Sneige, and A. El-Naggar Cytologic nuclear grading of fine needle aspirates of the breast carcinomas: concordance with histopathologic and flow data Mod Pathol 2 1990 14A
35. J. Moriguard, M. Gozlan-Fior, and D. Villemain Value of cytoprognostic classification in breast carcinomas J Clin Pathol 39 1986 489 496
36. E. Schulte, and C. Wittekind The influence of the wet-fixed Papanicolaou and air-dried Giemsa techniques on nuclear parameters in breast cancer cytology: a cytomorphometric study Diagn Cytopathol 3 1987 256 261
37. N. Sneige, S. Zachariah, and T.V. Fanning Fine-needle aspiration cytology of metastatic neoplasms in the breast Am J Clin Pathol 92 1 1989 27 35
38. S. Ciatto, R. Bonardi, and A. Herd-Smith Prognostic value of breast cancer cytologic grading: a retrospective study of 213 cases Diagn Cytopathol 9 1993 160 163
39. J. Harris, M. Lippman, and U. Veronsi Breast cancer N Engl J Med 327 1992 390 392
40. G.N. Hortobagyi, F.C. Ames, and A.W. Buzdar Management of Stage II primary cancer with primary chemotherapy, surgery and radiation therapy Cancer 62 1988 2507 2516
41. G.T. Beatson On treatment of inoperable cases of carcinoma of the mamma. Suggestions for new method of treatment with illustrated cases Lancet 2 1986 104
42. C. Huggins, and C.V. Hodges Studies on prostatic cancer. The effect of castration of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate Cancer Res 168 1 1941 9 12
43. C. Huggins, and D.M. Bergenstal Inhibition of human mammary and prostatic cancers by adrenalectomy Cancer Res 12 1952 134 141
44. R. Luft, H. Olivecrona, and J.D. Ikkos Hyphophysectomy in management of metastatic carcinoma of breast A. Currie Endocrine aspects of breast cancer. Proceedings of conference held at University of Glasgow 1958 Churchill Livingstone Edinburgh 27 35
45. H.S. Harris, and J.S. Spratt Bilateral adrenalectomy in metastatic mammary cancer: an analysis of sixty-four cases Cancer 23 1969 145 151
46. P.J. Folca, R.D. Glascock, and W.T. Irving Studies with tritium labelled hexestrol in advanced breast cancer Lancet 2 1961 796 798
47. D. Toft, and J. Gorski A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization Proc Natl Acad Sci USA 55 1966 1574 1581
48. E.V. Jensen Pattern of hormone receptor interactions K. Griffiths E.G. Pier-Repoint Some aspects of aetiology and biochemistry of prostatic cancer 1970 Alpha Omega Alpha 151 Cardiff (UK)
49. H. Mass, B. Engle, and H. Hohmeister Estrogen receptors in human breast cancer tissue Am J Obstet Gynecol 113 1972 337 382
50. E. Engelsman, J.P. Persijin, and C.B. Korsten Oestrogen receptors in human breast cancer tissue and response to endocrine therapy BMJ 2 1973 750 752
51. B.S. Leung, W.S. Fletcher, and T.D. Lindell Predictability of response to endocrine ablation in advanced breast carcinoma Arch Surg 106 1973 515 519
52. E.D. Savlov, W.L. Wittliff, and R. Hilf Correlation between certain biochemical properties of breast cancer and response to therapy. Preliminary report Cancer 33 1974 303 339
53. K.B. Harwitz, W.L. McGuire, and O.H. Pearson Predicting a response to endocrine therapy in human breast cancer. A hypothesis Science 189 1975 726 727
54. G.M. Clark, W.L. McGuire, and C.A. Hubray Progesterone receptors as a prognostic factor in Stage II breast cancer N Engl J Med 309 1983 1343 1347
55. S. Masood Estrogen and progesterone receptors in cytology Diagn Cytopathol 8 5 1992 475 491
56. S. Masood, L. Lu, and N. Rodenroth Potential value of estrogen receptor immunocyto-chemical assay in formalin fixed breast tumors Mod Pathol 3 1990 6,724 6,728
57. C.K. Osborne, M.G. Yachmowitz, and W.A. Knight The value of estrogen and progesterone receptors in the treatment of breast cancer Cancer 46 1980 2884 2888
58. E.R. Fisher, C.R. Osborne, and W.L. McGuire Correlation of primary breast cancer histopathology and estrogen receptor content Breast Cancer Res Treat 1 1981 37 41
59. L.G. Dressler, L.C. Seamer, and M.A. Owens DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens Cancer 61 1988 420 427
60. C.K. Osborne Receptors J.R. Harris S. Hellman I.C. Henderson Breast diseases 1987 JB Lippincott Company Phildelphia 210
61. J.P.A. Baak Mitosis counting in tumors Hum Pathol 21 1990 683 685
62. P.J. Van viest, and J.P.A. Baak The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients Hum Pathol 22 1990 326 330
63. F. Clayton Pathologic correlates of survival in 378 lymph node negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor Cancer 68 1991 1309 1317
64. J.S. Meyer, E. Friedman, and M. McCrate Predicition of early course of breast carcinoma by thymidine labelling Cancer 51 1983 1879 1886
65. M. Tubiana, M.N. Pejovic, and N. Charaudra The long term prognostic significance of the thymidine labeling index in breast cancer Int J Cancer 33 1984 441 445
66. J.S. Meyer, R.W. McDivitt, and K.R. Stone Practical breast carcinoma cell kinetics: review and update Breast Cancer Res Treat 4 1984 79 88
67. O.P. Kallioniemi, G. Blanco, and M. Alavaikko Tumour DNA ploidy as an independent prognostic factor in breast cancer Br J Cancer 56 5 1987 637 642
68. O.P. Kallinoiemi, G. Blanco, and M. Alavaikko Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer Cancer 62 10 1988 2183 2190
69. G.M. Clark, L.G. Dressler, and M.A. Owens Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry N Engl J Med 320 10 1989 627 633
70. W.E. Lewis Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients Cancer 65 10 1990 2315 2320
71. S. Keyhani-Rofagha, R.V. O'Toole, and W.B. Farrar Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 65 7 1990 1577 1582
72. S. Toikkanen, H. Joensuu, and P. Klemi The prognostic significance of nuclear DNA in invasive breast cancer - a study with long-term follow-up Br J Cancer 60 5 1989 693 700
73. H. Sigurdsson, B. Baldetorp, and A. Borg Indicators of prognosis in node-negative breast cancer N Engl J Med 322 15 1990 1045 1053
74. B. Fisher, N. Gunduz, and J. Costantino DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04 Cancer 68 7 1991 1465 1475
75. H. Johnson Jr., S. Masood, and C. Belluco Prognostic factors in node-negative breast cancer Arch Surg 127 1992 1386 1390
76. D.W. Hedley, G.M. Clark, and D.J. Cornelisse Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast Cytometry 14 1993 482 485
77. D.W. Hedley, C.A. Rugg, and R.D. Gelber Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer Cancer Res 47 17 1987 4729 4735
78. Stal O, Sullivan S, Wingren S, Carstensen J, et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A(13-14):2185-90.
79. H.B. Muss, T.E. Kute, and L.D. Case The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer Cancer 64 9 1989 1894 1900
80. H. Sigurdsson, B. Baldetorp, and A. Borg Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels Br J Cancer 62 5 1990 786 790
81. S.M. O'Reilly, R.S. Camplejohn, and D.M. Barnes DNA index, S-phase fraction, histological grade and prognosis in breast cancer Br J Cancer 61 5 1990 672 674
82. A.G. Falleninis, S.A. Franzen, and G.U. Auer Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphological factors. A retrospective study of 227 consecutive cases Cancer 62 3 1988 521 530
83. T.E. Kute Response to Beerman et al, "Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer." Cytometry 12 2 1991 155 156
84. D. Vielh Guides to clinical aspiration biopsy: flow cytometry 1991 Igaku-Shoin New York
85. S. Masood, and N. Hart Use of fine needle aspiration biopsy specimens in DNA flow cytometry study Am J Clin Pathol 92 1989 535(A)
86. F. Lopez, F. Bello, and F. Lacombe Modalities of synthesis of Ki-67 antigen during the stimulation of lymphocytes Cytometry 10 1989 731 738
87. G. Landberg, and G. Roos Flow cytometric analysis of proliferation associated nuclear antigen using washless staining of unfixed cells Cytometry 13 1992 230 240
88. M. Rishi, R. Schwarting, and A.J. Kovalich Detection of growth fraction in tumors by Ki-67 monoclonal antibody in cytologic smears: a prospective study of 40 cases Diagn Cytopathol 9 1993 52 56
89. M.J. Henry, M.W. Stanley, and B. Swenson Cytologic assessment of tumor cell kinetics. Applications of monoclonal antibody Ki-67 to fine needle aspiration smears Diagn Cytopathol 7 1991 591 596
90. S. Masood Prognostic factors in breast cancer, use of fine needle aspirates Acta Cytol 36 6 1992 S84 S96
91. M.J. Cline, J. Battifora, and J. Yokota Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease J Clin Oncol 5 1987 999 1000
92. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
93. A.K. Tandon, G.M. Clark, and G.C. Chambness HER-2/neu oncogene protein and prognosis in breast cancer J Clin Oncol 7 1989 1120 1128
94. S. Paik, R. Hazan, and E.R. Fisher Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic signficance of erbB-2 protein overexpression in primary breast cancer J Clin Oncol 8 1990 103 112
95. D. Allred, G.M. Clark, and A.K. Tandon HER-2/neu in node negative breast cancer. Prognostic significance of overexpression influenced by presence of in situ carcinoma J Clin Oncol 10 1992 599 605
96. S. Masood HER-2/neu oncogene expression in atypical hyperplasia, carcinoma in situ and invasive breast cancer Mod Pathol 4 1 1991 12A
97. J.G. Moore, V. To, and S.J. Patel HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections Diagn Cytopathol 23 2000 299 302
98. D. Gancberg, L. Lespagnard, and G. Ronas Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomoas. Correlation with oncogene amplification in 160 cases Am J Clin Pathol 113 2000 675 682
99. A. Mezzelani, L. Alasio, and C. Bartoli erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates Br J Cancer 80 1999 519 525
100. S. Masood, and M. Bui Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study Ann Clin Lab Sci 30 3 2000 259 265
101. D.T. McManus, A.H. Patterson, and P. Maxwell Fluorescence in situ hybridization detection of erbB2 amplification in breast cancer fine needle aspirates Mol Pathol 52 1999 75 77
102. C.A. Finlay, P.W. Hinds, and A.J. Levine The p53 proto-oncogenes can act as a suppressor of transformation Cell 57 1989 1083 1093
103. M. Bishop Molecular themes in oncogenes Cell 64 1991 235 248
104. R.J. Osborne, G.R. Merle, and T. Mitsudemi Mutations in p53 gene in primary human breast cancers Cancer Res 51 1991 6194 6198
105. A.D. Thor, D.H. Moso III, and S.M. Edgerton Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer J Natl Cancer Inst 84 1992 845 855
106. J. Isola, T. Wisakorpi, and K. Holli Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients J Natl Cancer Inst 84 1992 1109 1114
107. A.D. Thor, D.H. Moore, and S.M. Edgerton Increased accumulation of the p53 suppressor gene product is an independent prognostic variable for breast cancer J Natl Cancer Inst 84 1992 845 855
108. Addonizio LJ, Robbins RC. Pulmonary vascular resistance. In: Smith JK, editor. Proceedings of the Fourth International Symposium on Circulation. Las Vegas (NV): Real Science Press; 1987. p. 12-189.
109. S. Masood, R. Barnes, and B. Villas p53 oncosuppressor protein in carcinoma of the breast Mod Pathol 6 1 1991 80(a)
110. A.M. Davidoff, J.E. Herndon, and N.S. Glover Relation between p53 overexpression and established prognostic factors in breast cancer Surgery 110 1991 259 264
111. A. Faille, P.D. DeCremoux, and J.M. Extra p53 mutations and overexpression in locally advanced breast cancer Br J Cancer 69 6 1994 1145 1150
112. A.M. David, B.J. Kerns, and D. Iglehart Maintenance of p53 alterations throughout breast cancer progression Cancer Res 51 1991 2605 2610